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Table S1 Pre-hospital antithrombotic medication in STEMI and NSTE-ACS patients with or without a history of CVD. Values are n 
(%) unless otherwise indicated 
Resource Use Item 
STEMI  NSTE-ACS  







No History of 
CVD 









No History of 
CVD 





Any antiplatelet agent 256 (24.6) 1026 (26.6) 1282 (26.2) 0.19 358 (13.4) 465 (16.0) 823 (14.8) 0.01 <0.0001 
Aspirin 245 (23.5) 1011 (26.3) 1256 (25.6) 0.08 341 (12.8) 458 (15.8) 799 (14.3) <0.01 <0.0001 
Clopidogrel 123 (11.8) 508 (13.2) 631 (12.9) 0.24 89 (3.3) 105 (3.6) 194 (3.5) 0.56 <0.0001 
Prasugrel 5 (0.5) 34 (0.9) 39 (0.8) 0.20 2 (0.1) 5 (0.2) 7 (0.1) 0.31 <0.0001 
Ticlopidine 0 1 (0.0) 1 (0.0) … 0 0 0 … … 
Any GPIIb/IIIa inhibitor 4 (0.4) 23 (0.6) 27 (0.6) 0.41 1 (0.0) 3 (0.1) 4 (0.1) 0.36 <0.0001 
Any anticoagulant 131 (12.6) 571 (14.8) 702 (14.3) 0.07 113 (4.2) 139 (4.8) 252 (4.5) 0.32 <0.0001 
UFH 93 (8.9) 415 (10.8) 508 (10.4) 0.09 70 (2.6) 72 (2.5) 142 (2.5) 0.74 <0.0001 
LMWH 33 (3.2) 156 (4.0) 189 (3.9) 0.19 36 (1.3) 56 (1.9) 92 (1.6) 0.09 <0.0001 
Warfarin/acenocoumarol 5 (0.5) 0 5 (0.1) … 7 (0.3) 1 (0.0) 8 (0.1) 0.03 0.55 
Fondaparinux 2 (0.2) 4 (0.1) 6 (0.1) 0.47 1 (0.0) 13 (0.4) 14 (0.3) <0.01 0.13 
Dabigatran 0 0 0 … 1 (0.0) 0 1 (0.0) … … 
3 
Bivalirudin 0 1 (0.0) 1 (0.0) … 0 0 0 … … 
CVD, cardiovascular disease; LMWH, low-molecular-weight heparin; NSTE-ACS, non-ST-elevation myocardial infarction; SD, standard deviation; STEMI, ST-elevation 
myocardial infarction; UFH, unfractionated heparin. 
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Table S2 In-hospital CV medication in STEMI and NSTE-ACS patients with or without a history of CVD.* Values are n (%) unless 
otherwise indicated 
Resource Use Item 



















(n=5576) p Value 
At least one fibrinolytic   151 (14.5) 610 (15.8) 761 (15.5) 0.30 7 (0.3) 17 (0.6) 24 (0.4) 0.07 <0.0001 
TNK t-PA 69 (6.6) 257 (6.7) 326 (6.7) 0.96 4 (0.1) 5 (0.2) 9 (0.2) 0.83 <0.0001 
t-PA 24 (2.3) 102 (2.6) 126 (2.6) 0.54 0 0 0 … … 
r-PA 20 (1.9) 64 (1.7) 84 (1.7) 0.57 1 (0.0) 2 (0.1) 3 (0.1) 0.61 <0.0001 
Streptokinase 29 (2.8) 145 (3.8) 174 (3.6) 0.13 1 (0.0) 4 (0.1) 5 (0.1) 0.22 <0.0001 
Other 9 (0.9) 42 (1.1) 51 (1.0) 0.53 1 (0.0) 6 (0.2) 7 (0.1) 0.08 <0.0001 
At least one antiplatelet 
agent 
1041 (99.9) 3857 (100) 4898 (100) 0.05 2656 (99.4) 2895 (99.7) 5551 (99.6) 0.11 <0.0001 
Aspirin 995 (95.5) 3781 (98.0) 4776 (97.5) <0.0001 2490 (93.2) 2811 (96.8) 5301 (95.1) <0.0001 <0.0001 
Clopidogrel 940 (90.2) 3391 (87.9) 4331 (88.4) 0.04 2343 (87.7) 2616 (90.1) 4959 (88.9) <0.01 0.39 
Prasugrel 80 (7.7) 472 (12.2) 552 (11.3) <0.0001 97 (3.6) 162 (5.6) 259 (4.6) <0.001 <0.0001 
Any GPIIb/IIIa inhibitor 247 (23.7) 982 (25.5) 1229 (77.2) 0.25 195 (7.3) 321 (11.1) 516 (9.3) <0.0001 <0.0001 
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At least one anticoagulant 800 (76.8) 2983 (77.3) 3783 (77.2) 0.70 2067 (77.4) 2309 (79.5) 4376 (78.5) 0.05 0.12 
UFH 407 (39.1) 1641 (42.5) 2048 (41.8) 0.04 725 (27.1) 904 (31.1) 1629 (29.2) <0.01 <0.0001 
LMWH 468 (44.9) 1712 (44.4) 2180 (44.5) 0.76 1295 (48.5) 1465 (50.4) 2760 (49.5) 0.14 <0.0001 
Warfarin/acenocoumarol 70 (6.7) 82 (2.1) 152 (3.1) <0.0001 224 (8.4) 49 (1.7) 273 (4.9) <0.0001 <0.0001 
Fondaparinux 76 (7.3) 298 (7.7) 374 (7.6) 0.64 305 (11.4) 419 (14.4) 724 (13.0) <0.001 <0.0001 
Bivalirudin 23 (2.2) 99 (2.6) 122 (2.5) 0.51 14 (0.5) 29 (1.0) 43 (0.8) 0.04 <0.0001 
*Includes resource use in all hospitals, if patients were transferred. Data provided for in-hospital cardiovascular medication administered to ≥1% of patients with STEMI or 
NSTE-ACS. 
CVD, cardiovascular disease; GP, glycoprotein; LMWH, low-molecular-weight heparin; NSTE-ACS, non-ST-elevation myocardial infarction; SD, standard deviation; STEMI, 




Table S3 Independent predictors of duration of hospital stay (modelled as log[days]), using forward stepwise multiple regression on 
multivariable analysis* 




Z Statistic p Value 
Region    
Latin America vs Northern Europe 1.245 (1.206, 1.285) 13.60 <0.0001 
Southern Europe vs Northern Europe 1.097 (1.067, 1.127) 6.58 <0.0001 
Eastern Europe vs Northern Europe 1.029 (1.001, 1.058) 2.04 0.04 
Centre type    
 Other type of hospital/clinic vs regional/community/rural hospital 0.818 (0.785, 0.853) 9.43 <0.0001 
 University general hospital vs regional/community/rural hospital 0.940 (0.913, 0.966) 4.35 <0.0001 
 Non-university general hospital vs regional/community/rural hospital 0.949 (0.921, 0.977) 3.53 <0.001 
Killip Class 2/3/4 vs 1/unknown 1.166 (1.130, 1.204) 9.43 <0.0001 
LVEF <30% or severely reduced vs others 1.329 (1.243, 1.421) 8.29 <0.0001 
STEMI vs NSTE-ACS 1.084 (1.061, 1.107) 7.47 <0.0001 
Age (calculated) 1.003 (1.002, 1.004) 6.30 <0.0001 
Diabetes mellitus, yes vs no/unknown 1.073 (1.047, 1.100) 5.64 <0.0001 
Cath lab facilities, yes vs no/unknown 0.929 (0.905, 0.953) 5.57 <0.0001 
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Prior non-CVD, yes vs no/unknown 1.053 (1.028, 1.078) 4.28 <0.0001 
Peripheral vascular disease, yes vs no/unknown 1.102 (1.051, 1.154) 4.06 <0.0001 
Chronic CV medication, yes vs no/unknown 0.952 (0.927, 0.977) 3.72 <0.001 
Coronary angiogram diagnostic for CAD, yes vs no/unknown 0.937 (0.905, 0.971) 3.61 <0.001 
Hypertension, yes vs no/unknown 1.044 (1.019, 1.069) 3.54 <0.001 
Health care use in past 3 mo, yes vs no/unknown 1.041 (1.016, 1.067) 3.20 <0.01 
Hypercholesterolaemia, yes vs no/unknown 1.032 (1.011, 1.055) 2.93 <0.01 
Gender male vs female 0.969 (0.946, 0.993) 2.53 0.01 
Major bleeding in the previous 6 months, yes vs no/unknown 1.170 (1.036, 1.322) 2.52 0.01 
Family history of CHD, yes vs no/unknown 0.973 (0.952, 0.995) 2.37 0.02 
*n=10 568 observations read, n=10 566 used, n=2 with missing values. 
†
The ratio estimate provides the relative increase in duration of hospital stay (eg, 1.084 for STEMI vs NSTE-ACS means that STEMI patients spent an average 8.4% more time 
in hospital). 
CAD, coronary artery disease; CHD, coronary heart disease; CI, confidence interval; CV, cardiovascular; CVD, CV disease; LVEF, left ventricular ejection fraction; NSTE-ACS, 
non-ST-elevation acute coronary syndrome; STEMI, ST-elevation myocardial infarction. 
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Table S4 Independent predictors of in-hospital coronary revascularisation (PCI or CABG) on multivariable analysis* 
Variable Odds Ratio  
(95% CI) 
Z Statistic p Value 
Cath lab facilities, yes vs no/unknown 4.878 (4.319, 5.508) 25.55 <0.0001 
Region    
 Latin America vs Northern Europe 0.146 (0.126, 0.170) 24.78 <0.0001 
 Eastern Europe vs Northern Europe 0.412 (0.360, 0.472) 12.84 <0.0001 
 Southern Europe vs Northern Europe 0.778 (0.677, 0.893) 3.55 <0.001 
STEMI vs NSTE-ACS 2.558 (2.309, 2.835) 17.92 <0.0001 
Gender male vs female 1.568 (1.403, 1.753) 7.91 <0.0001 
Centre type
†
    
Non-university general hospital vs regional/community/rural hospital 0.585 (0.508, 0.673) 7.47 <0.0001 
University general hospital vs regional/community/rural hospital 0.706 (0.615, 0.810) 4.96 <0.0001 
Any cardiac disease (MI, prior PCI, prior CABG, or chronic angina), yes vs no/unknown 0.672 (0.582, 0.776) 5.42 <0.0001 
Atrial fibrillation, yes vs no/unknown 0.646 (0.521, 0.801) 3.99 <0.0001 
Family history of CHD, yes vs no/unknown 1.237 (1.110, 1.379) 3.84 0.0001 
Degree of dependence prior to index event    
 Non-severe dependence vs no dependence/unknown 0.675 (0.543, 0.839) 3.54 <0.001 
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 Severe dependence vs no dependence/unknown 0.439 (0.243, 0.793) 2.73 <0.01 
Heart failure, yes vs no/unknown 0.714 (0.570, 0.895) 2.93 <0.01 
Coronary angiogram diagnostic for CAD, yes vs no/unknown 1.253 (1.069, 1.470) 2.78 <0.01 
    
Time from symptom onset to hospital admission <1 h vs ≥1 h/unknown 1.360 (1.142, 1.620) 3.45 <0.001 
Current smoking vs never/unknown 1.155 (1.023, 1.304) 2.33 0.02 
Diabetes mellitus, yes vs no/unknown 0.883 (0.789, 0.989) 2.16 0.03 
*n=10 568 observations read, n=10 515 used. 
†
It should be noted that patients could be transferred to a different hospital for the purposes of PCI or CABG, then transferred back and enrolled in the study at discharge from 
the original hospital. For example, a patient enrolled at a rural hospital without cath lab facilities could be transferred to a university hospital for PCI, and then transferred back 
again. In this case, the PCI is attributed to the rural hospital that discharged the patient. For this reason, results shown here appear to indicate that less PCI/CABG was carried 
out in university and non-university hospitals vs regional/rural hospitals. 
CABG, coronary artery bypass graft; CAD, coronary artery disease; CHD, coronary heart disease; CI, confidence interval; CV, cardiovascular; CVD, CV disease; MI, 





Table S5 Multivariable analysis of variables potentially affecting in-hospital coronary revascularisation* 
 Odds Ratio  
(95% CI) Z Statistic p Value 
Cath lab facilities, yes vs no/unknown 4.878 (4.139, 5.508) 25.55 <0.0001 
Region    
Latin America vs Northern Europe 0.146 (0.126, 0.170) 24.78 <0.0001 
Eastern Europe vs Northern Europe 0.412 (0.360, 0.472) 12.84 <0.0001 
Southern Europe vs Northern Europe 0.778 (0.677, 0.893) 3.55 <0.001 
STEMI vs NSTE-ACS 2.558 (2.309, 2.835) 17.92 <0.0001 
Gender male vs female 1.568 (1.403, 1.753) 7.91 <0.0001 
Centre type
†
    
Non-university general hospital vs regional/community/rural hospital 0.585 (0.508, 0.673) 7.47 <0.0001 
University general hospital vs regional/community/rural hospital 0.706 (0.615, 0.810) 4.96 <0.0001 
Other type of hospital/clinic vs regional/community/rural hospital 1.181 (0.965, 1.446) 1.61 0.11 
Any cardiac disease (MI, prior PCI, prior CABG or chronic angina), yes vs no/unknown 0.672 (0.582, 0.776) 5.42 <0.0001 
Atrial fibrillation, yes vs no/unknown 0.646 (0.521, 0.801) 3.99 <0.0001 
Family history of CHD, yes vs no/unknown 1.237 (1.110, 1.379) 3.84 0.0001 
Degree of dependence prior to index event    
Non-severe vs no dependence/unknown 0.675 (0.543, 0.839) 3.54 <0.001 
Severe vs no dependence/unknown 0.439 (0.243, 0.793) 2.73 <0.01 
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Time from symptom onset to hospital admission <1 h vs ≥1 h/unknown 1.360 (1.142, 1.620) 3.45 <0.001 
Heart failure, yes vs no/unknown 0.714 (0.570, 0.895) 2.93 <0.01 
Coronary angiogram diagnostic for CAD, yes vs no/unknown 1.253 (1.069, 1.470) 2.78 <0.01 
Current smoking vs never/unknown 1.155 (1.023, 1.304) 2.33 0.02 
Diabetes mellitus, yes vs no/unknown 0.883 (0.789, 0.989) 2.16 0.03 
LVEF <30% or severely reduced vs others 0.740 (0.546, 1.003) 1.94 0.05 
Hypertension, yes vs no/unknown 1.088 (0.971, 1.220) 1.45 0.15 
Health care use in past 3 months, yes vs no/unknown 1.087 (0.970, 1.218) 1.44 0.15 
Major bleeding in the previous 6 months, yes vs no/unknown 1.410 (0.796, 2.498) 1.18 0.24 
Age (calculated) 0.997 (0.993, 1.002) 1.12 0.26 
Chronic CV medication, yes vs no/unknown 0.935 (0.825, 1.059) 1.06 0.29 
Peripheral vascular disease, yes vs no/unknown 0.913 (0.738, 1.129) 0.84 0.40 
Killip Class 2/3/4 vs 1/unknown 0.952 (0.820, 1.105) 0.65 0.52 
Prior non-CVD, yes vs no/unknown 0.967 (0.865, 1.081) 0.60 0.55 
Former smoking vs never/unknown 1.037 (0.920, 1.169) 0.59 0.56 
Hypercholesterolaemia, yes vs no/unknown 0.973 (0.879, 1.077) 0.53 0.60 
TIA/stroke, yes vs no/unknown 0.994 (0.802, 1.231) 0.06 0.95 
*n=10 568 observations read, n=10 515 used. 
†
See footnote under Table S4 
CABG, coronary artery bypass graft; CAD, coronary artery disease; CHD, coronary heart disease; CV, cardiovascular; CVD, cardiovascular disease; PCI, percutaneous 
coronary intervention; MI, myocardial infarction; TIA, transient ischaemic attack; LVEF, left ventricular ejection fraction. 
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Table S6 Multivariable analysis of variables potentially affecting any therapeutic procedure (resuscitation, mechanical ventilation, 
intra-aortic balloon pumping, temporary/permanent pacemaker, implantable cardiac defibrillator, cardiac resynchronisation 
therapy)* 
 Odds Ratio  
(95% CI) Z Statistic p Value 
STEMI vs NSTE-ACS 2.076 (1.754, 2.456) 8.51 <0.0001 
Killip Class 2/3/4 vs 1/unknown 2.000 (1.636, 2.446) 6.75 <0.0001 
LVEF <30% or severely reduced vs others 2.511 (1.766, 3.568) 5.13 <0.0001 
Region    
Eastern Europe vs Northern Europe 0.560 (0.441, 0.712) 4.75 <0.0001 
Latin America vs Northern Europe 1.186 (0.940, 1.497) 1.44 0.15 
Southern Europe vs Northern Europe 1.094 (0.893, 1.341) 0.87 0.38 
Centre type
†
    
Other type of hospital/clinic vs regional/community/rural hospital 0.606 (0.437, 0.840) 3.00 <0.01 
Non-university general hospital vs regional/community/rural hospital 0.775 (0.616, 0.975) 2.18 0.03 
University general hospital vs regional/community/rural hospital 0.948 (0.765, 1.176) 0.49 0.63 
Cath lab facilities, yes vs no/unknown 1.334 (1.081, 1.647) 2.68 <0.01 
Time from symptom onset to hospital admission <1 h vs ≥1 h/unknown 1.268 (0.998, 1.612) 1.94 0.05 
Family history of CHD, yes vs no/unknown 0.838 (0.701, 1.002) 1.93 0.05 
TIA/stroke, yes vs no/unknown 1.316 (0.951, 1.821) 1.66 0.10 
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Major bleeding in the previous 6 months, yes vs no/unknown 0.336 (0.081, 1.402) 1.50 0.13 
Age (calculated) 1.005 (0.998, 1.013) 1.41 0.16 
Heart failure, yes vs no/unknown 1.254 (0.880, 1.787) 1.25 0.21 
Hypercholesterolaemia, yes vs no/unknown 1.090 (0.925, 1.286) 1.03 0.30 
Prior non-CVD, yes vs no/unknown 0.910 (0.758, 1.092) 1.02 0.31 
Health care use in past 3 months yes vs no/unknown 1.098 (0.910, 1.324) 0.98 0.33 
Any cardiac disease (MI, prior PCI, prior CABG or chronic angina), yes vs no/unknown 0.890 (0.689, 1.149) 0.89 0.37 
Coronary angiogram diagnostic for CAD, yes vs no/unknown 1.137 (0.856, 1.509) 0.89 0.38 
Former smoking vs never/unknown 1.090 (0.897, 1.325) 0.87 0.39 
Atrial fibrillation, yes vs no/unknown 1.160 (0.819, 1.643) 0.84 0.40 
Peripheral vascular disease, yes vs no/unknown 1.136 (0.814, 1.587) 0.75 0.45 
Current smoking vs never/unknown 0.945 (0.776, 1.151) 0.56 0.58 
Degree of dependence prior to index event    
Non-severe vs no dependence/unknown 1.130 (0.799, 1.598) 0.69 0.49 
Severe vs no dependence/unknown 1.176 (0.485, 2.850) 0.36 0.72 
Chronic CV medication, yes vs no/unknown 0.944 (0.772, 1.155) 0.56 0.58 
Gender male vs female 1.048 (0.868, 1.266) 0.49 0.62 
Diabetes mellitus, yes vs no/unknown 0.964 (0.798, 1.165) 0.38 0.70 
Hypertension, yes vs no/unknown 1.004 (0.835, 1.209) 0.04 0.96 
*n=10 568 observations read, n=10 535 used. 
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†
It should be noted that patients could be transferred to a different hospital for the purposes of a therapeutic procedure, then transferred back and enrolled in the study at 
discharge from the original hospital. For example, a patient enrolled at a rural hospital could be transferred to a university hospital for intra-aortic balloon pumping, and then 
transferred back again. In this case, the procedure is attributed to the rural hospital that discharged the patient.  For this reason, results shown here appear to indicate that 
fewer therapeutic procedures were carried out in university and non-university hospitals vs regional/rural hospitals. 
CABG, coronary artery bypass graft; CAD, coronary artery disease; CHD, coronary heart disease; CV, cardiovascular; CVD, cardiovascular disease; PCI, percutaneous 
coronary intervention; MI, myocardial infarction; TIA, transient ischaemic attack; LVEF, left ventricular ejection fraction. 
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Table S7 Multivariable analysis of variables potentially affecting use of any fibrinolytic* 
 Odds Ratio  
(95% CI) Z Statistic p Value 
STEMI vs NSTE-ACS 25.915 (19.286, 34.823) 21.59 <0.0001 
Region    
Latin America vs Northern Europe 3.204 (2.594, 3.958) 10.80 <0.0001 
Southern Europe vs Northern Europe 1.458 (1.185, 1.794) 3.56 <0.001 
Eastern Europe vs Northern Europe 0.985 (0.789, 1.229) 0.14 0.89 
Cath lab facilities, yes vs no/unknown 0.427 (0.356, 0.512) 9.20 <0.0001 
Centre type
†
    
University general hospital vs regional/community/rural hospital 1.611 (1.291, 2.009) 4.23 <0.0001 
Non-university general hospital vs regional/community/rural hospital 1.458 (1.160, 1.833) 3.23 <0.01 
Other type of hospital/clinic vs regional/community/rural hospital 0.987 (0.728, 1.338) 0.09 0.93 
Prior non-CVD, yes vs   no/unknown 0.836 (0.694, 1.008) 1.87 0.06 
Age (calculated) 0.994 (0.987, 1.000) 1.83 0.07 
Any cardiac disease (MI, prior PCI, prior CABG or chronic angina), yes vs no/unknown 0.780 (0.594, 1.024) 1.79 0.07 
Atrial fibrillation, yes vs no/unknown 0.677 (0.391, 1.172) 1.39 0.16 
Current smoking vs never/unknown 1.104 (0.927, 1.315) 1.11 0.27 
Diabetes mellitus, yes vs no/unknown 1.103 (0.918, 1.326) 1.05 0.30 
Hypercholesterolaemia, yes vs no/unknown 1.080 (0.925, 1.261) 0.97 0.33 
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Major bleeding in the previous 6 months, yes vs no/unknown 0.588 (0.169, 2.048) 0.83 0.40 
Peripheral vascular disease, yes vs no/unknown 0.828 (0.524, 1.309) 0.81 0.42 
Time from symptom onset to hospital admission <1 h vs ≥1 h/unknown 1.090 (0.875, 1.359) 0.77 0.44 
LVEF <30% or severely reduced vs others 1.189 (0.751, 1.882) 0.74 0.46 
TIA/stroke, yes vs no/unknown 1.155 (0.761, 1.754) 0.46 0.50 
Hypertension, yes vs no/unknown 0.961 (0.808, 1.143) 0.45 0.65 
Heart failure, yes vs no/unknown 1.103 (0.634, 1.920) 0.35 0.73 
Health care use in past 3 months yes vs no/unknown 0.968 (0.794, 1.179) 0.33 0.74 
Family history of CHD, yes vs no/unknown 0.973 (0.827, 1.146) 0.32 0.75 
Killip Class 2/3/4 vs 1/unknown 0.964 (0.765, 1.214) 0.31 0.76 
Chronic CV medication, yes vs no/unknown 1.025 (0.852, 1.233) 0.26 0.79 
Degree of dependence prior to index event    
Non-severe vs no dependence/unknown 0.949 (0.611, 1.473) 0.23 0.82 
Severe vs no dependence/unknown 1.025 (0.334, 3.148) 0.04 0.97 
Coronary angiogram diagnostic for CAD, yes vs no/unknown 1.035 (0.738, 1.451) 0.20 0.84 
Former smoking vs never/unknown 1.010 (0.828, 1.233) 0.10 0.92 
Gender male vs female 1.004 (0.836, 1.207) 0.04 0.96 
*n=10 568 observations read, n=10 536 used. 
†
It should be noted that patients could be transferred to a different hospital for the purposes of fibrinolysis, then transferred back and enrolled in the study at discharge from the 
original hospital. For example, a patient enrolled at a rural hospital could be transferred to a university hospital for fibrinolysis, and then transferred back again. In this case, the 
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fibrinolysis is attributed to the rural hospital that discharged the patient. For this reason, results shown here appear to indicate that less fibrinolysis was carried out in university 
and non-university hospitals vs regional/rural hospitals. 
CABG, coronary artery bypass graft; CAD, coronary artery disease; CHD, coronary heart disease; CV, cardiovascular; CVD, cardiovascular disease; PCI, percutaneous 
coronary intervention; MI, myocardial infarction; TIA, transient ischaemic attack; LVEF, left ventricular ejection fraction. 
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Table S8 Independent predictors of any in-hospital therapeutic procedure (resuscitation, mechanical ventilation, intra-aortic balloon 
pumping, temporary/permanent pacemaker, implantable cardiac defibrillator, cardiac resynchronisation therapy) on multivariable 
analysis* 
Variable Odds Ratio  
(95% CI) 
Z Statistic p Value 
STEMI vs NSTE-ACS 2.076 (1.754, 2.456) 8.51 <0.0001 
LVEF <30% or severely reduced vs others 2.511 (1.766, 3.568) 5.13 <0.0001 
Killip Class 2/3/4 vs 1/unknown 2.000 (1.636, 2.446) 6.75 <0.0001 
Region    
Eastern Europe vs Northern Europe 0.560 (0.441, 0.712) 4.75 <0.0001 
Centre type
†
    
Other type of hospital/clinic vs regional/community/rural hospital 0.606 (0.437, 0.840) 3.00 <0.01 
Non-university general hospital vs regional/community/rural hospital 0.775 (0.616, 0.975) 2.18 0.03 
University general hospital vs regional/community/rural hospital 0.948 (0.765, 1.176) 0.49 0.6274 
Cath lab facilities, yes vs no/unknown 1.334 (1.081, 1.647) 2.68 <0.01 
*n=10 568 observations read, n=10 535 used. 
†
See footnote under Table S6. 
CI, confidence interval; LVEF, left ventricular ejection fraction; NSTE-ACS, non-ST-elevation acute coronary syndrome; STEMI, ST-elevation myocardial infarction. 
